Phase 1 N=18 Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers
Healthy
Primary: AUC0-∞ — 10600; 12400; 13600 nmol*h/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 This Study in Healthy Men Tests How the Body Takes up BI 1467335
Healthy
Primary: After the First Dose: Area Under the Concentration-time Curve of BI 1467335 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) of BI 1467335 (After…
Phase 1 N=6 A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte ([14C]-BI 425809 After iv Administration as Well as for BI 425809 After Oral Administration) Over the Time…
Phase 1 N=12 A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.
Healthy Volunteers Bioavailability Study
Primary: Absolute Bioavailability — 62.1 % of bioavailability
Phase 1 N=22 Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers
Healthy Volunteers
Primary: Percentage of Dose Excreted in Urine - MB Cohort — 3.81 Percentage
Phase 1 N=8 A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body
Healthy
Primary: Dose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) — 118.27; 161.69…
Phase 1 N=12 A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood
Healthy
Primary: Part 1: Area Under the Concentration-time Curve of BI 1358894 Over the Time Interval From 0 to Infinity After i.v. Administration and After Oral Administration…
Phase 1 N=14 A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
Healthy
Primary: Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞][dn]) — 21.36; 9.28 ng*hr/mL/mg
Phase 1 N=9 This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 and Stable Labelled Isotope BI 409306 (C-13/N-15) Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)…
Phase 1 N=18 A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers
Epilepsy
Primary: Number of Adverse Events Reported — 10; 7; 7 Number of adverse events reported
Phase 1 N=32 Relative Bioavailability and Food Effect Study of CVN424
Parkinson's Disease
Primary: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted…
Phase 1 N=6 A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet
Healthy
Primary: Area Under the Concentration-time Curve of BI 730357 Over the Time Interval From 0 to Infinity (Dose Normalized). — NA; NA mmol*h/L/kg
Phase 1 N=24 A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of RO7017773 (Part 1) — 1320; 1570; 1120; 1490 ng/mL
Phase 1 N=23 Bioavailability of Belumosudil (KD025) in Healthy Male Subjects
Bioavailability
Primary: Pharmacokinetics: Cmax of Dosing Regimen A (Tablets--Fasting) vs. Dosing Regimen B (Tablets--Fed) for KD025, KD025m1, and KD025m2 at 48 Hours Post-dose — 821; 2100…
Phase 1 N=48 Bioavailability Study of 2 Oral Formulations of ALXN1840
Healthy
Primary: Two-way Crossover Period: Maximum Observed Concentration (Cmax) For Plasma Total Molybdenum (Mo) — 227.0186; 238.2725 nanograms (ng)/milliliter (mL)
Phase 1 N=244 Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer
Health, Subjective
Primary: Incidence Rate of Drug Allergy Following ID Injection of the IP — 0; 0; 1; 0 Participants
Phase 1 N=70 Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers
Healthy
Primary: Number (%) of Subjects With Drug Related Adverse Events — 0.0; 33.3; 16.7; 0.0 Percentage of Participants
Phase 1 N=12 Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers
Healthy
Primary: AUC0-infinity of Plasma Deleobuvir — 19300 nmol*h/L
Phase 1 N=24 Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) at Concentration at or Above Lower Limit of Quantitation (LLOQ) of…
Phase 1 N=83 Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
Healthy
Primary: Number of Participants With Drug-related Adverse Events (AE) — 3; 1; 2; 1 Participants
Phase 1 N=16 A Study Investigating the Absolute Oral Bioavailability of Balovaptan After Single and Multiple Daily Oral Doses of Balovaptan in Healthy Volunteers
Healthy Volunteers
Primary: Absolute Bioavailability of Oral Balovaptan at Dose Level A (Cohort 1) — 100.6 Percentage
Phase 1 N=12 A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 1265162 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Dose-normalized, (AUC0-∞, Norm) — 44.63; 0.22…
Phase 1 N=81 Safety of Single Rising Doses and Relative Bioavailability of BI 691751
Healthy
Primary: AUC0-72h (Part II) — 2740; 3050; 2800 nmol*h/L
Phase 1 N=18 A Study in Healthy Men and Women to Test Whether BI 1358894 Influences the Amount of Bupropion in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of Bupropion in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2953; 2795 hours *…
Phase 1 N=12 Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
Parkinson
Primary: Cmax - Maximum Observed Plasma Concentration — 635.0; 238.2 ng/mL
Phase 1 N=96 Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)
Healthy
Primary: Percentage of Subjects With Drug Related Adverse Events (AEs) in Part I — 46.7; 50.0; 44.4; 66.7 Percentage of participants
Phase 1 N=24 Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 16.7; 44.4; 11.1 Percentage of participants
Phase 1 N=12 A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07817883 — 2308; 2579; 4266; 3566 nanogram per milliliter (ng/mL)
Phase 1 N=67 Bioequivalence Study of Tacrolimus in Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Concentration (AUC 72) — 37434.51; 33716.80 pg.h/mL
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2275.77; 2166.70…